Open original FDA record ↗Recall record
- FDA identifier
- Z-0364-2019
- Company in FDA record
- Baxter Healthcare Corporation
- FDA classification date
- Nov 2, 2018
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Potential ability to leak once used for compounding.
Source facts
- Action
- An Urgent Product Recall communication will be sent to affected customers via U.S.P.S., first class mail. Baxter is asking customers to: 1. Locate and remove all affected product from your facility. 2. Contact Baxter Healthcare Center for Service to arrange for return and credit. 3. Complete the enclosed Baxter Customer Reply Form and return it to Baxter by either fax or email. Notification Effectiveness: 100%. The non-responding customers will be contacted via telephone. Expansion on 02/19/2019, Baxter notified customers (and additional customers) of recall and additional lots included.
- Initiated
- 2018-09-12
- Root cause
- Process control
- Terminated
- 2020-11-02
- Distribution
- Worldwide distribution - US Nationwide in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, WA, WI, and WV. Countries of Canada, Australia, New Zealand, China, Hong Kong, Brazil, Chile, and Uruguay.
- Recall number
- Z-0364-2019
- Recall status
- Terminated
- CDRH record ID
- 167904
- FDA classified
- 2018-11-02
- Recall event number
- 81240